Influence of deep hyperthermia combined with systemic chemotherapy on survival of patients with recurrent metastatic colorectal cancer and the prognostic factors

张凤春,徐海燕,崔洪全,徐迎春,汪娟,刘万美,王蒙,陈彬
DOI: https://doi.org/10.3781/j.issn.1000-7431.2016.44.507
2016-01-01
Tumori
Abstract:Objective: To investigate the effect of tumor deep hyperthermia combined with systemic chemotherapy on survival of patients with recurrent metastatic colorectal cancer and the prognostic factors. Methods: One hundred and eight patients with recurrent metastatic colorectal cancer were divided into thermo-chemotherapy group (n = 53, receiving deep thermo-chemotherapy combined with chemotherapy with XELOX regimen) and chemotherapy group (n = 55, receiving chemotherapy with XELOX regimen). The overall survival (OS) was compared between two groups. In the thermo-chemotherapy group, the relationships of pretreatment serum albumin (ALB), serum prealbumin (PA) and peripheral blood neutrophil/lymphocyte ratio (NLR) with prognosis were evaluated. Results: The median survival time was significantly longer in the thermo-chemotherapy group than in the chemotherapy group (23 vs 18 months, P = 0.032). In the thermo-chemotherapy group, the OS of patients with serum ALB level ≥35 g/L, serum PA level ≥ 200 g/L and peripheral blood NLR u003c 3.3 were superior to those of patients with serum ALB level u003c 35 g/L (median survival time: 35 vs 11 months, P = 0.001), serum PA level u003c 200 g/L (median survival time: 39 vs 13 months, P = 0.001) and peripheral blood NLR ≥3.3 (median survival time: 35 vs 13 months, P = 0.040). Conclusion: For recurrent metastatic colorectal cancer, thermotherapy combined with chemotherapy may be an effective treatment option to improve the survival. The serum ALB and PA levels and the peripheral blood NLR may predict the prognosis of patients with recurrent metastatic colorectal cancer receiving thermo-chemotherapy. DOI:10.3781/j.issn.1000-7431.2016.44.507
What problem does this paper attempt to address?